We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Insmed (INSM) Starts Dosing in Phase III Bronchiectasis Study
Read MoreHide Full Article
Insmed Incorporated (INSM - Free Report) announced that it has dosed the first patient in the phase III ASPEN study, which evaluated its novel, oral, first-in-class pipeline candidate brensocatib for treating patients with bronchiectasis– a severe chronic pulmonary disorder.
The double-blind, placebo-controlled ASPEN study will evaluate the safety, efficacy and tolerability of brensocatib for the given indication. The primary endpoint of the study will check the rate of pulmonary exacerbations over the 52-week treatment period. The company plans to enroll approximately 1,620 patients in the above-mentioned study. Notably, patients with bronchiectasis caused due to cystic fibrosis might not be enrolled in the study.
Shares of Insmed were up 1.6% following the announcement of the news on Wednesday. In fact, the stock has rallied 66.5% so far this year compared to the industry’s increase of 3.8%.
Brensocatib, a reversible inhibitor of dipeptidyl peptidase 1, is being developed for the treatment of patients with bronchiectasis and other inflammatory diseases.
Per the company, data from the phase II WILLOW study showed that treatment with brensocatib prolonged the time to first exacerbation as well as reduced the risk of exacerbation over a 24-week treatment period. Based on the strong result from the WILLOW study, the company initiated the registrational ASPEN study.
We note that the FDA has granted a Breakthrough Therapy Designation to brensocatib for addressing patients with bronchiectasis.
In November 2020, the European Medicines agency also granted a Priority Medicines (PRIME) tag to brensocatib for the treatment of non-cystic fibrosis bronchiectasis (“NCFBE”). The prestigious tag was based on positive data from the phase II WILLOW study which evaluated brensocatib in adults with NCFBE.
Catalyst Biosciences’ loss per share estimates have narrowed 13.2% for 2020 and 7.7% for 2021 over the past 60 days.
Halozyme’s earnings estimates have been revised 29.5% upward for 2020 and 19.4% for 2021 over the past 60 days. The stock has skyrocketed 129.3% year to date.
Aptose Biosciences’ loss per share estimates have narrowed 10.3% for 2020 and 4.7% for 2021 over the past 60 days. The stock has rallied 19.2% year to date.
These Stocks Are Poised to Soar Past the Pandemic
The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.
Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.
Image: Bigstock
Insmed (INSM) Starts Dosing in Phase III Bronchiectasis Study
Insmed Incorporated (INSM - Free Report) announced that it has dosed the first patient in the phase III ASPEN study, which evaluated its novel, oral, first-in-class pipeline candidate brensocatib for treating patients with bronchiectasis– a severe chronic pulmonary disorder.
The double-blind, placebo-controlled ASPEN study will evaluate the safety, efficacy and tolerability of brensocatib for the given indication. The primary endpoint of the study will check the rate of pulmonary exacerbations over the 52-week treatment period. The company plans to enroll approximately 1,620 patients in the above-mentioned study. Notably, patients with bronchiectasis caused due to cystic fibrosis might not be enrolled in the study.
Shares of Insmed were up 1.6% following the announcement of the news on Wednesday. In fact, the stock has rallied 66.5% so far this year compared to the industry’s increase of 3.8%.
Brensocatib, a reversible inhibitor of dipeptidyl peptidase 1, is being developed for the treatment of patients with bronchiectasis and other inflammatory diseases.
Per the company, data from the phase II WILLOW study showed that treatment with brensocatib prolonged the time to first exacerbation as well as reduced the risk of exacerbation over a 24-week treatment period. Based on the strong result from the WILLOW study, the company initiated the registrational ASPEN study.
We note that the FDA has granted a Breakthrough Therapy Designation to brensocatib for addressing patients with bronchiectasis.
In November 2020, the European Medicines agency also granted a Priority Medicines (PRIME) tag to brensocatib for the treatment of non-cystic fibrosis bronchiectasis (“NCFBE”). The prestigious tag was based on positive data from the phase II WILLOW study which evaluated brensocatib in adults with NCFBE.
Zacks Rank & Stocks to Consider
Insmed currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the biotech sector include Catalyst Biosciences, Inc. , Halozyme Therapeutics, Inc. (HALO - Free Report) and Aptose Biosciences, Inc. (APTO - Free Report) , all carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Catalyst Biosciences’ loss per share estimates have narrowed 13.2% for 2020 and 7.7% for 2021 over the past 60 days.
Halozyme’s earnings estimates have been revised 29.5% upward for 2020 and 19.4% for 2021 over the past 60 days. The stock has skyrocketed 129.3% year to date.
Aptose Biosciences’ loss per share estimates have narrowed 10.3% for 2020 and 4.7% for 2021 over the past 60 days. The stock has rallied 19.2% year to date.
These Stocks Are Poised to Soar Past the Pandemic
The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.
Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.
See the 5 high-tech stocks now>>